Long-Term Temporal Trends of Real-World Healthcare Costs Associated . . . Nivolumab plus ipilimumab (NIVO + IPI) and pembrolizumab plus axitinib (PEM + AXI) are first-line (1L) treatments for advanced or metastatic renal cell carcinoma (aRCC), although the long-term trends in their associated real-world healthcare costs are not well defined
Checkpoint Inhibitor Prices Dropped Marginally Over Decade Average sales prices of five drugs (pembrolizumab, nivolumab, avelumab, dostarlimab, and retifanlimab) remained within 7% of each other, and five newer drugs (cemiplimab, atezolizumab, durvalumab
EE64 Temporal Trends in Healthcare Costs Associated with First-Line (1L . . . While immuno-oncology combinations have become the standard of care for aRCC, real-world cost comparisons remain limited This study aims to assess and compare all-cause and RCC-related healthcare costs for patients receiving 1L N+I vs P+L treatment for aRCC
Long-Term Temporal Trends of Real-World Healthcare Costs . . . - Springer Nivolumab plus ipilimumab (NIVO + IPI) and pembrolizumab plus axitinib (PEM + AXI) are first-line (1L) treatments for advanced or metastatic renal cell carcinoma (aRCC), although the long-term trends in their associated real-world healthcare costs are not well defined
A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus . . . We aimed to assess the cost-effectiveness of the three combination therapies currently approved in treatment-naïve advanced or metastatic renal cell carcinoma—nivolumab + ipilimumab (NI), pembrolizumab + axitinib (PA), and avelumab + axitinib (AA)—from a US payer perspective
Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the . . . Meaning The findings suggest that first-line treatment with nivolumab-ipilimumab combination therapy is not cost-effective at current prices despite clinical trial data indicating that this therapy increases overall survival among patients with advanced non–small cell lung cancer